So great to see continued investor interest in the MHC-targeting space https://t.co/GKLBpvtrHp #MHC, further validating CDR-Life’s vision of pursuing highly specific T cell engagers in solid tumors.
What will #JPM23 and a return to in-person activities bring?
Sara Michelmore shares her expectations on how the meeting will set the tone for 2023 in our latest #MacDougallMusings: https://t.co/RsEQD7Xa5s
Attending JPM? Contact [email protected] to set up a meeting.
We polled the top 14 pharma companies on their partnering plans for #JPM22#JPM2022#JPMWeek. 5 of the 14 said they were not sending any BD teams and the balance said they were sending smaller teams.
As employers begin to prepare for the return to the office, how can they ease the transition after over a year of remote work? In May’s #MacDougallMusings, Carolyn Noyes discusses how strong internal communications can help align expectations company-wide: https://t.co/bhgQvGUOuM
As we continue to grow, MacDougall is looking for science-minded communicators and strategists to support our #biotech and #lifesciences clients. View our current openings: https://t.co/TrSf1g10sc #scicomms#hiringnow
The #MacDougall team loved participating in the Hope Reads program through @Thehopefactory, where we read our favorite children's books for children in hospitals and in shelters to listen to!
Congratulations to #MacDougall#client@PsiOxus on their data announcement with @bluebirdbio, validating the potential of the T-SIGn vectors to be used in combination with various #IO therapies! $BLUE
"What should we do with the JPMorgan healthcare conference going digital?" Join MacDougall co-founder, @macbiodoug as he and others answer this question Wednesday. @CRUSHLifeSci#JPM2021#LifeSciences https://t.co/iV1BBnC5Pt
👀 A state to watch: Massachusetts. With a new $7B+ record for funding this year, the state recorded 20 deals of $100M+, largely in #biotech & #healthcare:
@ateapharma: $215M Series D
@EQRxINC: $200M Series A
@C4Therapeutics: $150M Series B
https://t.co/Zm5xc0iG7K